# Caris Life Sciences, Inc.: overview CAI · Nasdaq · CIK 2019410 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cai.md) · [Financials](/companies/cai/financials.md) · [Filings](/companies/cai/filings.md) · [Insiders](/companies/cai/insiders.md) Latest reported revenue: [$263.7m](/filings/0002019410-26-000055.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0002019410-26-000055). ## Last eight quarters | Line item | Unit | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [102](/filings/0002019410-25-000028.md) | [130 d](/filings/0002019410-26-000016.md) | [121](/filings/0002019410-26-000044.md) | [181](/filings/0002019410-26-000055.md) | [217](/filings/0002019410-25-000028.md) | [293 d](/filings/0002019410-26-000016.md) | [216](/filings/0002019410-26-000044.md) | [264](/filings/0002019410-26-000055.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(59.9%)](/filings/0002019410-25-000028.md) | [(28.5%) d](/filings/0002019410-26-000016.md) | [(47.9%)](/filings/0002019410-26-000044.md) | [(9.9%)](/filings/0002019410-26-000055.md) | [15.1%](/filings/0002019410-25-000028.md) | [30.2% d](/filings/0002019410-26-000016.md) | [2.4%](/filings/0002019410-26-000044.md) | [10.2%](/filings/0002019410-26-000055.md) | | Net margin | % | [(66.6%)](/filings/0002019410-25-000028.md) | [(28.4%) d](/filings/0002019410-26-000016.md) | [(84.8%)](/filings/0002019410-26-000044.md) | [(39.6%)](/filings/0002019410-26-000055.md) | [11.2%](/filings/0002019410-25-000028.md) | [28.0% d](/filings/0002019410-26-000016.md) | [(0.2%)](/filings/0002019410-26-000044.md) | [(0.2%)](/filings/0002019410-26-000055.md) | | Diluted EPS | $ per share | [(2.59)](/filings/0002019410-25-000028.md) | not reported | [(3.57)](/filings/0002019410-26-000044.md) | [(7.97)](/filings/0002019410-26-000055.md) | [0.08](/filings/0002019410-25-000028.md) | not reported | [0.00](/filings/0002019410-26-000044.md) | [0.00](/filings/0002019410-26-000055.md) | | Free cash flow | $m | [(71.3) d](/filings/0002019410-25-000028.md) | [(41.2) d](/filings/0002019410-26-000016.md) | [(34.0)](/filings/0002019410-26-000044.md) | [5.9 d](/filings/0002019410-26-000055.md) | [55.3 d](/filings/0002019410-25-000028.md) | [39.7 d](/filings/0002019410-26-000016.md) | [22.5](/filings/0002019410-26-000044.md) | [6.4 d](/filings/0002019410-26-000055.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2023-12-31) | FY (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | | Revenue | $m | [306](/filings/0002019410-26-000016.md) | [412](/filings/0002019410-26-000016.md) | [812](/filings/0002019410-26-000016.md) | | Gross margin | % | not reported | not reported | not reported | | Operating margin | % | [(104.4%)](/filings/0002019410-26-000016.md) | [(62.4%)](/filings/0002019410-26-000016.md) | [5.6%](/filings/0002019410-26-000016.md) | | Net margin | % | [(111.5%)](/filings/0002019410-26-000016.md) | [(68.4%)](/filings/0002019410-26-000016.md) | [(8.4%)](/filings/0002019410-26-000016.md) | | Diluted EPS | $ per share | [(13.24)](/filings/0002019410-26-000016.md) | [(10.66)](/filings/0002019410-26-000016.md) | [(3.22)](/filings/0002019410-26-000016.md) | | Free cash flow | $m | [(298)](/filings/0002019410-26-000016.md) | [(254)](/filings/0002019410-26-000016.md) | [66.9](/filings/0002019410-26-000016.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cai/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $551.1m | 30,923,878 | | Added +138,293 | | [J. H. Whitney Equity Partners VI, LLC](/funds/1394517.md) | 2026-06-30 | $200.6m | 11,256,615 | | Reduced −7,000,000 | | [COATUE MANAGEMENT LLC](/funds/1135730.md) | 2026-06-30 | $175.0m | 9,819,992 | | Unchanged | | [BRAIDWELL LP](/funds/1920938.md) | 2026-06-30 | $147.1m | 8,256,032 | | Added +246,585 | | [Sixth Street Partners Management Company, L.P.](/funds/1812095.md) | 2026-06-30 | $130.6m | 7,327,041 | | Reduced −7,058,358 | | [PointState Capital LP](/funds/1509842.md) | 2026-06-30 | $121.7m | 6,828,835 | | Reduced −531,611 | | [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $120.2m | 6,558,514 | | Added +3,098,299 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $98.7m | 5,536,798 | | Added +679,686 | | [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $86.3m | 4,844,431 | | Added +1,085,969 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $76.3m | 4,280,238 | | Added +951,217 | ## Recent filings [All 131 filings](/companies/cai/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-14 | 16:38 ET | [8-K](/filings/0002019410-26-000061.md) | 7.01 Regulation FD disclosure | 0002019410-26-000061 | | 2026-08-05 | 17:00 ET | [10-Q](/filings/0002019410-26-000055.md) | Quarterly report, period 2026-06-30 | 0002019410-26-000055 | | 2026-08-05 | 16:12 ET | [8-K](/filings/0002019410-26-000053.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0002019410-26-000053 | | 2026-06-05 | 17:03 ET | [8-K](/filings/0002019410-26-000046.md) | 5.07 Shareholder vote results | 0002019410-26-000046 | | 2026-05-08 | 16:13 ET | [10-Q](/filings/0002019410-26-000044.md) | Quarterly report, period 2026-03-31 | 0002019410-26-000044 | | 2026-05-07 | 16:14 ET | [8-K](/filings/0002019410-26-000040.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0002019410-26-000040 | | 2026-04-23 | 06:23 ET | [DEF 14A](/filings/0002019410-26-000032.md) | Proxy statement, period 2026-06-04 | 0002019410-26-000032 | | 2026-04-02 | 16:28 ET | [8-K](/filings/0002019410-26-000019.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation | 0002019410-26-000019 | | 2026-03-03 | 16:09 ET | [10-K](/filings/0002019410-26-000016.md) | Annual report, period 2025-12-31 | 0002019410-26-000016 | | 2026-02-26 | 16:11 ET | [8-K](/filings/0002019410-26-000011.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0002019410-26-000011 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0002019410-26-000016.md), filed Mar 3, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/c4a87037-95d8-4be1-8101-79c835eb08f9) ## About the filer - CIK: 2019410 - Tickers: CAI - Exchange: Nasdaq - SIC code: 8071 Services-Medical Laboratories - State of incorporation: TX - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.